Education about the illness and medication is important for all patients, so that they understand their condition and to improve medication adherence.[212]Katschnig H. Rehabilitation in schizophrenia - guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80.
http://www.ncbi.nlm.nih.gov/pubmed/9746970?tool=bestpractice.com
Unfortunately there is a current lack of evidence-based guidance on communicating a diagnosis of schizophrenia initially.[213]Farooq S, Johal RK, Ziff C, et al. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Cochrane Database Syst Rev. 2017 Oct 24;(10):CD011707.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD011707.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29064090?tool=bestpractice.com
Factors to discuss include prognosis and treatment options; this can be challenging given that these may vary substantially between patients, and also because the patient may be acutely ill. It is vital that patients consistently take their medication. Any changes should be under the supervision of a specialist. Stopping medication abruptly can be dangerous as the symptoms are likely to return, which can result in functional decline and danger to self and others. Gradual, monitored reduction of antipsychotic medication over a period of months is also more likely to lead to relapse than continuing on maintenance treatment, and does not improve social functioning.[214]Moncrieff J, Crellin N, Stansfeld J, et al. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial. Lancet Psychiatry. 2023 Nov;10(11):848-59.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(23)00258-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/37778356?tool=bestpractice.com
Patients should be advised that maintenance on antipsychotic drugs prevents relapse. In a Cochrane analysis of 75 randomised controlled trials, the chance of relapse at 7-12 months was 24% with antipsychotic treatment compared with 61% with placebo.[125]Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/32840872?tool=bestpractice.com
This effect must be weighed against the adverse effects of antipsychotic drugs.[125]Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008016.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/32840872?tool=bestpractice.com
If the patient experiences uncomfortable adverse effects, these issues should be discussed with their physician and appropriate medication adjustments made.
Ensure patients, carers, and key-workers are aware of the early signs of relapse and how to access help.[133]Lean M, Fornells-Ambrojo M, Milton A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry. 2019 May;214(5):260-8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499726
http://www.ncbi.nlm.nih.gov/pubmed/30898177?tool=bestpractice.com
Identify and aim to modify risk factors that increase the chance of relapse. These are:[68]Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.
https://journals.sagepub.com/doi/10.1177/0269881119889296
http://www.ncbi.nlm.nih.gov/pubmed/31829775?tool=bestpractice.com
[133]Lean M, Fornells-Ambrojo M, Milton A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry. 2019 May;214(5):260-8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499726
http://www.ncbi.nlm.nih.gov/pubmed/30898177?tool=bestpractice.com
[134]Semple D, Smyth R. Oxford handbook of psychiatry. 3rd ed. Oxford: Oxford University Press; 2013.
Poor adherence to medication[135]Alphs L, Nasrallah HA, Bossie CA, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol. 2016 Jul;31(4):202-9.
https://journals.lww.com/intclinpsychopharm/Fulltext/2016/07000/Factors_associated_with_relapse_in_schizophrenia.4.aspx
http://www.ncbi.nlm.nih.gov/pubmed/26974214?tool=bestpractice.com
Presence of persistent psychotic symptoms[133]Lean M, Fornells-Ambrojo M, Milton A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry. 2019 May;214(5):260-8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499726
http://www.ncbi.nlm.nih.gov/pubmed/30898177?tool=bestpractice.com
Lack of insight
Substance misuse.[136]Colizzi M, Carra E, Fraietta S, et al. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res. 2016 Feb;170(2-3):311-7.
http://www.ncbi.nlm.nih.gov/pubmed/26718334?tool=bestpractice.com
Address alcohol and substance misuse and encourage smoking cessation.[1]National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].
https://www.nice.org.uk/guidance/cg178
[87]Public Health England. NHS RightCare toolkit: physical ill-health and CVD prevention in people with severe mental Illness. March 2019 [internet publication].
https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2019/03/nhs-rightcare-toolkit-cvd-prevention.pdf
Smoking is a major contributor to increased mortality in individuals with serious mental illness.[9]American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, third edition. 2021 [internet publication].
https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841
[127]Reynolds RJ, Day SM, Shafer A, et al. Mortality rates and excess death rates for the seriously mentally ill. J Insur Med. 2018;47(4):212-9.
https://meridian.allenpress.com/jim/article/47/4/212/73465/Mortality-Rates-and-Excess-Death-Rates-for-the
http://www.ncbi.nlm.nih.gov/pubmed/30653378?tool=bestpractice.com
[128]Tam J, Warner KE, Meza R. Smoking and the reduced life expectancy of individuals with serious mental illness. Am J Prev Med. 2016 Dec;51(6):958-66.
http://www.ncbi.nlm.nih.gov/pubmed/27522471?tool=bestpractice.com
People with schizophrenia are more likely to smoke than the general population but are less likely to be offered support to quit.[87]Public Health England. NHS RightCare toolkit: physical ill-health and CVD prevention in people with severe mental Illness. March 2019 [internet publication].
https://www.england.nhs.uk/rightcare/wp-content/uploads/sites/40/2019/03/nhs-rightcare-toolkit-cvd-prevention.pdf
[129]Gilbody S, Peckham E, Bailey D, et al. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. Lancet Psychiatry. 2019 May;6(5):379-90.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546931
http://www.ncbi.nlm.nih.gov/pubmed/30975539?tool=bestpractice.com
Physical activity should be recommended to improve symptoms, cognition, and quality of life.[215]Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018 Oct;54:124-44.
http://www.ncbi.nlm.nih.gov/pubmed/30257806?tool=bestpractice.com